2023
Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
Fesharaki-Zadeh A, Lowe N, Arnsten A. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports 2023, 3: 100154. DOI: 10.1016/j.nerep.2022.100154.Peer-Reviewed Original ResearchN-acetylcysteineCognitive deficitsΑ2A-adrenoceptor agonistsPrefrontal cortexCOVID19 infectionPlacebo-controlled trialOpen-label treatmentCommon side effectsExecutive functionPFC connectionsBrain fogAcid blockadeLabel treatmentHypotensive episodesGuanfacine treatmentNMDA receptorsPatient brieflySide effectsClinical experienceGuanfacineCognitive impairmentPatientsPrefrontal connectivityDemonstrate efficacyPrefrontal function
2019
Chronic Traumatic Encephalopathy: A Brief Overview
Fesharaki-Zadeh A. Chronic Traumatic Encephalopathy: A Brief Overview. Frontiers In Neurology 2019, 10: 713. PMID: 31333567, PMCID: PMC6616127, DOI: 10.3389/fneur.2019.00713.Peer-Reviewed Original ResearchChronic traumatic encephalopathyTraumatic brain injuryRepetitive mild traumatic brain injuryPost-traumatic brain injuryMild traumatic brain injuryPeri-vascular regionsRisk factor genesAmerican football playersTraumatic encephalopathyAPOE4 carriersSubtle presentationBrain injuryTBI treatmentTeam physiciansNeuropathological signatureNeuropsychiatric assessmentPhosphorylated tauCognitive impairmentCombat settingNeurodegenerative diseasesDiseaseMilitary veteransDistinct phenotypesSubtypesFootball players